(lp0
S'AVEO Pharmaceuticals, Inc.  Shares Tumble on the Back of Stock Dilution Smarter Analyst - 17 hours ago AVEO Pharmaceuticals, Inc.  investors are having a rough morning, after the drug maker announced that it has priced an underwritten public offering of 30,000,000 shares of common stock at a price to the public of $0.50 per share, a 23%&nbsp;...AVEO Announces Proposed Offering of Common Stock - Business Wire AVEO Pharmaceuticals, Inc.  Lowered to Sell at Zacks Investment Research - Chaffey Breeze'
p1
aS"Aveo reeling after FDA's rejection of kidney cancer drug Boston Globe - Aug 26, 2013 It took Aveo Pharmaceuticals Inc. seven years to develop a much anticipated kidney cancer drug. Federal regulators needed only about four hours to crush the company's hopes."
p2
aS"AVEO Pharmaceuticals, Inc.  Files An 8-K Results of Operations ... Market Exclusive - Mar 22, 2017 AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's platform delivers insights into cancer and related disease.AVEO Reports Full Year 2016 Financial Results and Provides Business Update - Business Wire "
p3
aS"Traders Secrets on Kronos Worldwide, Inc. , AVEO Pharmaceuticals, Inc.  StockNewsJournal - Mar 24, 2017 The average of this ratio is -2.54 for the industry and sector's best figure appears 13.01. AVEO Pharmaceuticals, Inc. , at its latest closing price of $0.71, it has a price-to-book ratio of 18.03, compared to an industry average at 9.84 ...AVEO Pharmaceuticals Inc. - Receive News &amp; Ratings Daily - BBNSNew Analyst Ratings On AVEO Pharmaceuticals, Inc.  - NewsDen"
p4
aS"AVEO Pharmaceuticals  Q4 Earnings: What's in Store? Yahoo Finance - Mar 7, 2017 AVEO Pharmaceuticals, Inc. AVEO is expected to report fourth-quarter 2016 results this month. The company has an impressive track record for the last four reported quarters having beaten estimates on three occasions and meeting expectations in one with&nbsp;..."
p5
aS"Company Update : AVEO Pharmaceuticals, Inc. Announces Dosing of ... Smarter Analyst - May 26, 2016 AVEO Pharmaceuticals, Inc.  announced that the first patient has been dosed in the Company's pivotal TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory&nbsp;..."
p6
aS"AVEO Pharmaceuticals  Pays $4M to Settle SEC Fraud Charges StreetInsider.com - Mar 29, 2016 The SEC alleges that AVEO Pharmaceuticals Inc.  concealed the FDA's level of concern about Tivozanib in public statements to investors by omitting the critical fact that FDA staff had recommended a second clinical trial to address their&nbsp;...Aveo Pharmaceuticals to pay $4 million to settle kidney drug case - ReutersSEC charges biotech Aveo with misleading investors - The Boston Globe"
p7
aS'Stock Update : AVEO Pharmaceuticals, Inc. Reports 3Q:16 Financial ... Smarter Analyst - Nov 4, 2016 In the last 18 months, we have made important progress in moving forward both elements of our strategy, including our oncology pipeline, for which we have retained significant North American rights, and our non-oncology pipeline, which is being ...'
p8
aS'Stock Returns: AVEO Pharmaceuticals Inc  versus CTI BioPharma ... CML News - Mar 13, 2017 This is a snapshot to compare the stock returns for AVEO Pharmaceuticals Inc  versus CTI BioPharma Corp.  .'
p9
aS'Traders Take Note: AVEO Pharmaceuticals Inc  Stock Drops ... CML News - Mar 25, 2017 Take Note: AVEO Pharmaceuticals Inc  has hit some technical weakness in its momentum, and while it has not broken down all the way through support -- watch the key levels that we discuss below and further, watch the stochastics and&nbsp;...'
p10
a.